Flowonix Medical of New Jersey, and Colorado-based Cerebral Therapeutics, announced the first patients implanted with the Prometra. ADDRESS is the first multi-center dose ranging clinical study assessing intracerebroventricular (ICV) delivery of the drug valproate (valproate sodium) in patients with focal seizures, with temporal lobe onset with or without secondary generalisation.